zika
viru
zikv
belong
genu
flaviviru
flavivirida
famili
relat
dengu
viru
denv
yellow
fever
viru
yfv
japanes
enceph
viru
jev
west
nile
viru
wnv
global
distribut
mosquito
speci
aed
genu
vector
mani
flaviviru
also
transmit
zikv
howev
zikv
remain
rel
minor
obscur
caus
human
diseas
second
half
centuri
featur
limit
number
scientif
report
fact
autochthon
human
infect
describ
outsid
africa
continent
feder
state
micronesia
sinc
report
brazil
chronicl
rapidli
spread
epidem
coexist
denv
chikungunya
viru
chikv
epidem
spread
north
mosquitoborn
transmiss
report
mani
nation
america
far
north
mexico
southern
florida
omin
zikv
implic
caus
agent
fetal
development
problem
report
zikvassoci
birth
defect
primarili
brain
abnorm
microcephali
infant
born
mother
infect
zikv
viru
recov
amniot
fluid
placent
brain
tissu
zikv
infect
classifi
ongo
threat
world
health
organ
unit
state
center
diseas
control
prevent
issu
guidanc
manag
infect
gener
popul
pregnant
women
infant
due
recent
report
sexual
transmit
zikv
infect
cdc
also
develop
guidelin
prevent
mode
transmiss
recent
zikv
transmiss
also
describ
miami
florida
suggest
autochthon
spread
could
occur
region
us
inhabit
aed
spp
treatment
varieti
human
ailment
use
mab
revolution
abil
amelior
human
suffer
infecti
diseas
ebola
epidem
highlight
potenti
util
cocktail
three
neutral
n
mab
block
infect
ebola
viru
convincingli
administr
singl
nmab
five
day
post
infecti
viru
exposur
prevent
develop
diseas
ebolainfect
macaqu
mab
engin
prevent
antibodydepend
enhanc
incorpor
lala
mutat
reduc
bind
promis
intervent
flavivir
therapi
longterm
goal
use
cocktail
lalamut
nmab
prevent
zikv
infect
atrisk
individu
primarili
pregnant
women
therapeut
nmab
must
potent
order
clinic
viabl
nmab
isol
strategi
base
identif
hightit
antigenselect
repertoir
somat
hypermut
shm
germin
center
gc
b
cell
provid
basi
select
b
cell
produc
ab
increas
hallmark
adapt
humor
respons
featur
conserv
among
mammal
highlight
import
ab
affin
enhanc
evolutionari
fit
thu
unsurpris
vast
major
human
ab
memori
immunoglobulin
ig
g
pool
undergon
affin
matur
averag
nucleotid
substitut
precursor
gene
contribut
shm
abmedi
viral
neutral
particularli
clear
chronicallyinduc
broadli
neutral
antibodi
hiv
revers
antihiv
nmab
precursor
germlin
antibodi
result
drastic
reduct
complet
loss
viral
neutral
although
mutat
mab
found
secondari
denv
infect
role
mutat
acut
virusneutr
clearanc
less
clear
still
preval
thought
antivir
ab
respons
involv
engag
poor
nonneutr
germlin
clone
gener
v
j
rearrang
follow
shmmediat
refin
germin
center
enhanc
neutral
potenc
describ
isol
plasmablastderiv
human
mab
sort
day
post
onset
symptom
zikvpati
paulo
brazil
patient
report
previou
histori
dengu
infect
yellow
fever
vaccin
tabl
isol
ab
neutral
zikv
rel
high
concentr
interestingli
one
mab
exhibit
nucleotid
mutat
compar
correspond
germlin
sequenc
still
recogn
zikv
immunodomin
epitop
neutral
viru
result
suggest
unforeseen
role
gcindepend
respons
zikv
possibl
virus
blood
sampl
collect
volunt
woman
report
prurigin
skin
rash
start
six
day
prior
begin
acut
neurolog
deficit
suggest
gb
zikv
infect
confirm
posit
realtim
reversetranscriptas
pcr
assay
zikv
rna
urin
sampl
collect
day
onset
first
rash
symptom
blood
cerebrospin
fluid
neg
zikv
rna
previou
histori
singl
dengu
infect
yellow
fever
immun
also
report
peripher
blood
mononuclear
cell
pbmc
obtain
blood
sampl
collect
day
post
onset
symptom
blood
sampl
patient
obtain
sign
written
consent
form
approv
univers
paulo
institut
review
board
cappesq
anonym
plasma
sampl
volunt
brazil
us
obtain
convalesc
subject
rtpcrconfirm
zikv
denv
infect
tabl
four
volunt
donat
sampl
post
yellow
fever
vaccin
determin
frequenc
plasmablast
circul
cytometr
analysi
pbmc
obtain
blood
collect
acid
citrat
dextros
acd
use
ficollpaqu
ge
lifesci
gradient
briefli
stain
fresh
pbmc
sampl
x
cell
room
temperatur
dark
cocktail
contain
follow
fluorophoreantibodi
conjug
phycoerythrin
pe
antihuman
clone
becton
dickinson
bd
antihuman
clone
bd
allophycocyanin
apc
cyanin
cy
antihuman
clone
bd
peridinin
chlorophyl
protein
complex
percp
antihuman
clone
bd
apc
antihuman
antibodi
clone
biolegend
fluorescein
isothiocyan
fitc
antihuman
clone
bd
pe
antihuman
clone
bd
also
includ
fixabl
viabil
dye
fixabl
red
dead
cell
stain
kit
life
technolog
stain
mix
order
discrimin
live
dead
cell
min
wash
cell
twice
fac
buffer
pb
fb
mm
edta
resuspend
pb
solut
store
acquisit
day
sampl
acquir
use
bd
facsaria
iiu
flow
cytomet
analyz
use
flowjo
flowjo
plasmablast
popul
defin
live
cell
see
gate
sort
strategi
fig
use
plasmablast
stain
fresh
pbmc
sampl
x
cell
sort
bd
facsaria
ii
flow
cytomet
singl
plasmablast
cell
sort
plate
contain
lysi
buffer
design
extract
preserv
rna
mm
trishcl
ph
mm
kcl
mm
mm
dtt
ngwell
yeast
trna
life
technolog
u
rnase
inhibitor
new
england
biolab
neb
igep
sigma
sort
rna
plate
immedi
frozen
dri
ice
subsequ
clone
ab
chain
conduct
revers
transcript
follow
nest
pcr
amplifi
variabl
region
immunoglobulin
ig
chain
use
describ
protocol
minor
modif
briefli
cdna
synthes
reaction
use
origin
sort
plate
reaction
contain
ng
random
hexam
idt
mm
dntp
life
technolog
superscript
iii
revers
transcriptas
life
technolog
molecular
biolog
grade
water
singl
sort
cell
sampl
lysi
buffer
describ
revers
transcript
reaction
perform
min
min
min
min
reaction
complet
cdna
store
heavi
light
chain
amplifi
three
differ
nest
pcr
reaction
use
mix
vspecif
primer
match
primer
constant
region
igg
igl
igk
pcr
reaction
conduct
use
hotstartaq
plu
dna
polymeras
qiagen
second
set
pcr
reaction
carri
primer
redesign
incorpor
restrict
site
compat
subclon
rhesu
express
vector
instead
origin
human
vector
sequenc
amplifi
clone
product
use
primer
complementari
ig
constant
region
sequenc
analyz
use
igblast
imgtvquest
identifi
v
j
gene
rearrang
well
shm
level
express
mab
thermofish
human
cell
line
plasmid
encod
heavi
light
chain
cotransfect
use
expifectamin
transfect
kit
thermofish
day
harvest
secret
mab
supernat
ig
concentr
supernat
determin
antirhesu
igg
elisa
proceed
function
assay
experi
purifi
mab
use
protein
plu
pierc
contain
column
remov
impur
concentr
purifi
protein
determin
measur
absorb
nm
nanodrop
thermo
scientif
bind
determin
viru
captur
assay
vca
recombin
r
e
elisa
vca
plate
coat
overnight
mouseantiflaviviru
monoclon
antibodi
clone
emd
millipor
follow
incub
viral
stock
zikv
denv
elisa
plate
coat
zikv
e
protein
mybiosourc
dilut
ml
pb
coat
step
plate
wash
pb
mab
sampl
dilut
ml
ad
design
well
incub
h
subsequ
plate
wash
detect
carri
use
goat
antihuman
igg
hrp
secondari
ab
southern
biotech
ad
well
dilut
follow
h
incub
plate
wash
develop
tmb
substrat
room
temperatur
min
plate
develop
tmb
substrat
room
temperatur
min
reaction
stop
tmb
solut
absorb
read
nm
neutral
potenc
mab
measur
use
flow
cytometrybas
assay
brief
recombin
mab
transfect
supernat
purifi
dilut
preincub
zikv
paraiba
refer
denv
serotyp
final
volum
h
viru
mab
mixtur
ad
onto
well
plate
confluent
vero
cell
monolay
duplic
new
seed
vero
cell
obtain
american
type
cultur
collect
atcc
repositori
studi
inoculum
incub
incub
one
hour
agit
plate
everi
min
one
hour
viru
mabcontain
supernat
aspir
well
wash
media
fresh
media
ad
plate
incub
total
hour
cell
trypsin
trypsin
life
technolog
fix
bd
cytofix
permeabil
bd
cytoperm
viral
infect
detect
antibodi
millipor
recogn
zikv
denv
follow
stain
antimous
apc
fluorophoreconjug
secondari
reagent
biolegend
concentr
achiev
halfmaxim
neutral
calcul
use
nonlinear
regress
analysi
prism
softwar
graphpad
softwar
inc
follow
strain
use
neutral
assay
zikv
paraiba
pac
prnt
conduct
previous
describ
briefli
purifi
serial
dilut
optimem
supplement
human
serum
albumin
vwr
fetal
bovin
serum
gentamicin
zikv
paraiba
dilut
final
concentr
pfu
ml
diluent
ad
equal
volum
dilut
ab
virusmab
mixtur
incub
min
cell
cultur
medium
remov
confluent
monolay
cultur
vero
cell
plate
virusab
mixtur
transfer
onto
duplic
cell
monolay
cell
monolay
incub
min
overlaid
methylcellulos
optimem
supplement
fb
glutamin
ml
gentamicin
sampl
incub
four
day
plaqu
visual
immunoperoxidas
stain
plaquereduct
neutral
titer
calcul
inhibit
mab
bind
determin
elisa
begin
elisa
plate
coat
mous
antiflaviviru
monoclon
antibodi
emd
millipor
dilut
carbon
bind
buffer
incub
overnight
next
day
plate
wash
five
time
well
block
skim
milk
pb
block
step
plate
wash
viru
sampl
ad
design
well
incub
room
temperatur
subsequ
plate
wash
pb
correspond
block
plasma
sampl
ad
follow
plasma
block
plate
wash
ad
correspond
well
h
detect
use
rhesu
iggspecif
antibodi
mous
antimonkey
igghrp
clone
southern
biotech
thereaft
plate
wash
well
develop
tmb
substrat
room
temperatur
min
reaction
stop
tmb
stop
solut
absorb
determin
nm
isol
plasmablast
patient
present
suspect
syndrom
gb
tabl
first
day
symptom
patient
previou
histori
dengu
infect
yellow
fever
vaccin
tabl
previous
healthi
woman
present
emerg
room
report
progress
paresthesia
mainli
extrem
hand
along
acut
intermitt
pain
left
forearm
previou
four
day
physic
examin
patient
present
grade
iv
asymmetr
muscular
weak
hypoesthesia
left
limb
abolish
deep
tendon
reflex
lower
limb
mild
weak
left
facial
muscl
also
note
patient
report
respiratori
disord
hoars
sign
dysautonomia
detect
clinic
evalu
fever
conjunct
myalgia
joint
pain
absent
ill
afterward
patient
hospit
clinic
diagnosi
gb
intraven
human
ig
ivig
treatment
initi
dosag
g
kg
day
day
cerebrospin
fluid
analysi
electroneuromyogram
perform
fourth
fifth
day
neurolog
symptom
onset
respect
result
within
normal
limit
electroneuromyogram
repeat
day
neurolog
symptom
signific
abnorm
note
despit
persist
weak
patient
left
leg
arm
treatment
ivig
patient
present
transient
worsen
hemiparesi
progress
recov
cours
week
discharg
hospit
day
postneurolog
symptom
onset
physic
exam
reveal
signific
improv
muscular
strength
abolish
deep
tendon
reflex
lower
limb
remitt
skin
rash
clear
complet
day
initi
emerg
blood
cerebrospin
fluid
urin
sampl
collect
day
neurolog
symptom
detect
zikv
rtpcr
urin
sampl
zikvposit
pcr
blood
cerebrospin
fluid
neg
saliva
sampl
collect
neg
zikv
isol
plasmablast
peripher
blood
mononuclear
cell
pbmc
collect
day
tabl
well
contain
singlesort
cell
amplifi
clone
sequenc
heavi
light
ab
chain
use
primer
complementari
v
gene
segment
primer
anneal
constant
igg
region
result
pair
heavi
light
chain
tabl
eight
mab
bound
zikv
fig
seven
mab
exhibit
crossreact
one
denv
serotyp
singl
exclus
zikv
interestingli
two
mab
bound
denv
zikv
test
neutral
potenc
zikvspecif
mab
flowbas
neutral
assay
plaqu
reduct
neutral
test
prnt
found
neutral
zikv
approxim
ml
fig
analysi
isol
antibodi
variabl
v
domain
sequenc
reveal
five
mab
averag
gene
mutat
level
nucleotid
modif
two
mab
nucleotid
substitut
mab
unusu
low
level
shm
isotypeswitch
mab
lower
chang
tabl
highli
mutat
mab
zikvspecif
bind
tabl
fact
eight
zikvbind
mab
lowest
shm
level
includ
four
mab
lack
clearli
recogniz
mutat
compar
put
heavi
light
chain
germlin
precursor
tabl
fig
except
junction
divers
zikvneutr
mab
heavi
chain
exhibit
sign
antigenselect
ig
diversif
ident
sequenc
ig
heavi
chain
variabl
ighv
gene
segment
amino
acid
prior
intern
immunogenet
inform
system
imgt
howev
posit
site
junction
ighv
igh
divers
ighd
germlin
refer
interestingli
region
part
segment
nongermlin
nucleotid
correspond
six
amino
acid
identifi
ighv
ighd
gene
fig
segment
like
result
n
nucleotid
addit
gener
b
cell
ig
gene
rearrang
prior
antigen
select
lack
mutat
elsewher
sequenc
like
substitut
also
gener
development
step
downstream
sequenc
correspond
junction
igh
join
ighj
gene
also
reveal
similar
nucleotid
insert
likewis
kappa
k
chain
junction
gene
also
contain
one
insert
although
rule
possibl
shmmediat
nucleotid
chang
n
insert
region
mutat
identifi
remaind
region
heavi
light
chain
thu
mab
like
close
ident
origin
v
j
gene
rearrang
b
cell
antigen
contact
investig
whether
recogn
immunodomin
zikv
epitop
use
serolog
block
assay
brief
assay
detect
presenc
compet
ab
inhibit
mab
bind
epitop
bind
recombin
e
protein
fig
use
whole
viru
bind
assay
captur
zikv
plate
use
mab
panflaviviru
incub
zikv
plasma
patient
divers
histori
denv
zikv
exposur
tabl
ad
unlabel
engin
rhesu
constant
region
detect
bind
mab
use
hrplabel
mous
antirhesu
mab
fig
nine
ten
plasma
sampl
individu
infect
zikv
block
bind
blind
test
fig
tabl
similar
block
activ
observ
regardless
whether
individu
previous
infect
denv
vaccin
yellow
fever
contrast
littl
block
activ
observ
denv
plasma
absenc
prior
zikv
exposur
fig
furthermor
recognit
specif
observ
denvonli
infect
individu
thu
serolog
block
assay
accur
predict
previou
zikv
exposur
confirm
rtpcr
one
patient
plasma
sampl
test
although
patient
donor
posit
urin
rtpcr
result
zikv
plasma
block
bind
zikv
tabl
interestingli
plasma
exhibit
detect
zikvneutr
activ
suggest
patient
mount
measur
antibodi
respons
zikv
conclus
plasma
inhibit
zikv
infect
vero
cell
contain
antibodi
show
igg
mab
detect
shm
gener
zikv
earli
infect
remark
despit
germlineencod
mab
zikvspecif
bind
four
denv
serotyp
furthermor
mab
neutral
zikv
also
bind
immunodomin
epitop
viru
remark
despit
germlineencod
bind
specif
zikv
crossreact
four
denv
serotyp
result
also
suggest
recogn
uniqu
epitop
zikv
unclear
ab
develop
specif
without
shm
final
find
suggest
affin
matur
necessari
gener
isotyp
switch
virusneutr
ab
low
level
shm
ab
possess
neutral
activ
previous
report
mice
human
support
idea
germlineencod
mab
inde
neutral
ab
low
level
shm
also
report
acut
phase
human
denv
infect
clear
ab
contribut
antivir
neutral
activ
studi
mice
vsvspecif
mab
lack
shm
isol
previous
interestingli
secondari
primari
mous
ab
vsv
mutat
furthermor
revers
mutat
ab
nonmut
precursor
reduc
abrog
vsv
bind
neutral
activ
bind
differ
mutat
germlin
ab
much
less
pronounc
might
expect
addit
mice
conduct
shm
due
aid
knockout
still
mount
neutral
ab
respons
friend
viru
strain
murin
leukemia
viru
suggest
ab
lack
extens
shm
undergo
gcindepend
development
pathway
although
mechanist
basi
phenomenon
remain
elucid
rapid
gcindepend
respons
might
particularli
relev
control
acut
cytopath
virus
gcindepend
ab
would
aris
quickli
infect
curtail
viral
replic
prevent
virusmedi
damag
even
provoc
hangartn
et
al
argu
cytopath
virus
specif
evolv
retain
bind
germlin
sequenc
decreas
host
lethal
increas
fit
hand
chronic
virus
may
evolv
avoid
germlinebind
develop
neutral
respons
persist
far
hypothes
remain
unsubstanti
lack
evid
strictli
germlin
neutral
ab
respons
human
experi
specif
design
detect
gcindepend
respons
seem
like
isotypeswitch
origin
directli
germlin
precursor
isol
zikvinfect
individu
develop
neurolog
complic
compat
gb
treat
ivig
underli
factor
influenc
potenti
associ
gb
zikv
infect
might
involv
autoimmun
process
could
influenc
develop
immun
respons
addit
ivig
may
role
select
ab
respons
mount
peripher
b
cell
repertoir
unlik
howev
sinc
patient
initi
ivig
treatment
day
plasmablast
isol
possibl
gb
ivigtreat
influenc
develop
potenti
associ
difficult
determin
outsid
scope
studi
clear
howev
respons
exclus
volunt
bind
block
serum
zikvinfect
individu
fig
recent
describ
zikvspecif
mab
deriv
epsteinbarr
memori
b
cell
highli
polyclon
undergon
shm
howev
shm
level
human
antizikv
mab
lower
shm
level
mab
isol
respons
primari
infect
vaccin
sar
cov
rabi
vaccin
recurr
chronic
infect
rsv
piv
staphylococcu
aureu
klebsiella
pneumonia
hcmv
hcv
autoimmun
diseas
wang
et
al
recent
report
isol
new
zikvspecif
mab
memori
b
cell
three
littl
shm
mab
isol
memori
cell
sort
solubl
monomer
zikv
e
protein
contrast
bind
recombin
protein
contrast
isol
zikvspecif
mab
circul
plasmablast
peak
recal
memori
bcell
deriv
plasmablast
thought
occur
within
first
week
postsecondari
infect
thu
probabl
isol
mab
memoryb
cell
origin
remain
possibl
plasmablast
sort
basal
popul
circul
low
frequenc
blood
conclus
isol
mab
use
differ
b
cell
method
suggest
antizikv
mab
germlin
characterist
limit
specif
b
cell
subtyp
notabl
antizikv
mab
isol
date
less
mutat
mab
isol
relat
denv
infect
togeth
find
suggest
possibl
differ
develop
ab
respons
zikv
unfortun
despit
effort
unabl
map
bind
site
first
employ
vitro
escap
assay
result
singl
mutat
consensu
sequenc
also
bind
prme
protein
express
cell
preclud
abil
map
interact
use
alamut
envelop
panel
character
interact
thu
requir
signific
effort
beyond
scope
current
manuscript
mab
retain
abil
bind
virion
conclus
bind
conform
epitop
base
cohort
human
plasma
sampl
test
studi
appear
zikvinfect
individu
mount
ab
respons
epitop
recogn
epitop
recogn
ab
individu
previous
infect
zikv
therebi
prevent
bind
contrast
ab
plasma
individu
previous
infect
denv
serotyp
prevent
bind
may
therefor
potenti
diagnost
sever
diagnost
option
test
zikv
exposur
exist
includ
rtpcr
igm
elisa
prnt
method
rel
straightforward
detect
zikv
nucleic
acid
acut
phase
blood
urin
saliva
semen
proven
difficult
design
rapid
effect
diagnost
zikv
exposur
chronic
phase
sampl
collect
first
week
symptom
initi
test
antizikv
antidenv
antichikv
viru
igm
elisa
howev
patient
receiv
flavivir
vaccin
denv
yfv
jev
andor
infect
flavivirus
past
assay
may
difficult
interpret
due
crossreact
ab
thu
posit
igm
test
need
confirm
labori
prnt
assay
igm
antibodi
persist
week
serum
sera
individu
previous
infect
week
would
also
confirm
viru
neutralizationbas
method
plasma
inhibit
assay
may
perhap
provid
altern
techniqu
studi
isol
plasmablastderiv
ab
zikvinfect
individu
unusu
characterist
human
igg
limit
shm
yet
bind
immunodomin
zikv
epitop
present
four
denv
serotyp
furthermor
mab
neutral
viru
approxim
ml
result
suggest
shmindepend
pathway
may
gener
neutral
ab
respons
zikv
